Palvella Therapeutics, Inc. (PVLA) shareholders
Close on Nov 17, 2026Market cap $2.08BP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Kaupinen Wes Joint filing with Christine L. Kaupinen (13.90%), Wesley H. Kaupinen 2019 Irrevocable Trust dated February 28, 2019 (6.90%) and 2 more | 1,644,869 | 14.60% | 13D (active) | Dec 13, 2024 |
| Jennison Associates LLC | 1,101,652 | 7.70% | 13G (passive) amendment | Sep 30, 2026 |
| Prudential Financial Inc | 962,374 | 6.70% | 13G (passive) | Jun 30, 2026 |
| Bvf Partners L P/Il Joint filing with Bvf Inc/Il (7.10%), Lampert Mark N (7.10%) and 1 more | 879,009 | 7.10% | 13G (passive) amendment | Dec 31, 2025 |
| Aaron Cowen Joint filing with Suvretta Capital Management, LLC (7.40%), Averill Master Fund, Ltd. (6.50%) | 822,400 | 7.40% | 13G (passive) amendment | Sep 30, 2025 |
| BlackRock, Inc. | 812,953 | 5.70% | 13G (passive) | Jun 30, 2026 |
| Mathew P. Arens Joint filing with First Light Asset Management, LLC (5.34%) | 769,117 | 5.34% | 13G (passive) amendment | Jun 30, 2026 |
| Frazier Life Sciences Public Fund, L.P. Joint filing with Fhmlsp, L.P. (6.00%), Fhmlsp, L.L.C. (6.00%) | 706,360 | 6.00% | 13G (passive) amendment | Dec 31, 2025 |
| James N. Topper Joint filing with Patrick J. Heron (6.30%), Albert Cha (6.20%) and 1 more | 690,012 | 6.30% | 13G (passive) amendment | Mar 31, 2025 |
| Samsara BioCapital GP, LLC Joint filing with Samsara BioCapital, L.P. (6.10%), Srinivas Akkaraju (6.10%) | 679,486 | 6.10% | 13G (passive) | Dec 13, 2024 |
| ADAR1 Capital Management, LLC Joint filing with ADAR1 Capital Management GP, LLC (10.50%), Daniel Schneeberger (10.50%) | 138,641 | 10.50% | 13G (passive) | Jul 24, 2024 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of PVLA | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Suvretta Capital Management, LLC | 1,135,406 | 7.88% | $173.51M | −18,090 | 3.17% |
| Jennison Associates LLC | 960,619 | 6.67% | $146.80M | +320,008 | 0.09% |
| BlackRock, Inc. | 918,357 | 6.37% | $140.34M | +231,504 | 0.00% |
| Frazier Life Sciences Management, L.P. | 882,400 | 6.12% | $134.85M | – | 2.94% |
| First Light Asset Management, LLC | 771,901 | 5.36% | $117.96M | −208,857 | 7.17% |
| Bvf Inc/Il | 672,789 | 4.67% | $102.82M | −288,200 | 2.63% |
| State Street Corp | 653,172 | 4.53% | $99.82M | +194,173 | 0.00% |
| Price T Rowe Associates Inc /Md/ | 638,868 | 4.43% | $97.63M | +236,304 | 0.01% |
| Vanguard Capital Management LLC | 513,794 | 3.57% | $78.52M | +36,500 | 0.00% |
| Frontier Capital Management Co LLC | 478,833 | 3.32% | $73.18M | +104,798 | 0.68% |
| Federated Hermes, Inc. | 433,015 | 3.01% | $66.17M | – | 0.10% |
| Woodline Partners LP | 317,517 | 2.20% | $48.52M | – | 0.15% |
| Orbimed Advisors LLC | 292,360 | 2.03% | $44.68M | +157,760 | 0.83% |
| Geode Capital Management, LLC | 276,164 | 1.92% | $42.21M | +70,555 | 0.00% |
| Siren, L.L.C. | 257,485 | 1.79% | $39.35M | – | 0.80% |
| Primecap Management Co/Ca/ | 256,182 | 1.78% | $39.15M | +61,152 | 0.02% |
| Alliancebernstein L.P. | 253,168 | 1.76% | $31.56M | −9,667 | 0.01% |
| Eventide Asset Management, LLC | 231,484 | 1.61% | $35.38M | −1,764 | 0.47% |
| Emerald Advisers, LLC | 229,486 | 1.59% | $35.07M | +67,986 | 0.83% |
| FMR LLC | 214,841 | 1.49% | $32.83M | −967 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 197 | 14M | 97.8% | 38 / 89 | 43 / 19 | 2M | 2M |
| Q1 2026 | 180 | 13M | 92.0% | 65 / 65 | 30 / 22 | 5M | 1M |
| Q4 2025 | 140 | 10M | 67.7% | 53 / 41 | 30 / 12 | 3M | 2M |
| Q3 2025 | 100 | 9M | 59.2% | 43 / 23 | 20 / 8 | 4M | 1M |
| Q2 2025 | 65 | 6M | 41.0% | 26 / 19 | 9 / 2 | 2M | 1M |
| Q1 2025 | 41 | 5M | 35.6% | 15 / 9 | 4 / 7 | 1M | 0M |
| Q4 2024 | 33 | 4M | 28.0% | 33 / 0 | 0 / 0 | 4M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
179 funds held PVLA in Q2 2026, 34% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of PVLA | Value | % of fund | As of |
|---|---|---|---|---|---|
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 408,678 | 2.84% | $62.45M | 0.58% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 388,390 | 2.70% | $59.35M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 281,586 | 1.95% | $43.03M | 0.05% | Jun 30, 2026 |
| Federated Hermes Kaufmann Fund | 276,556 | 1.92% | $38.45M | 0.78% | Jul 31, 2026 |
| Eventide Healthcare & Life Sciences Fund | 231,484 | 1.61% | $35.38M | 1.98% | Jun 30, 2026 |
| PRIMECAP Odyssey Aggressive Growth Fund | 209,825 | 1.46% | $29.17M | 0.39% | Jul 31, 2026 |
| PGIM Jennison Small Company Fund | 202,900 | 1.41% | $31.01M | 0.89% | Jun 30, 2026 |
| PGIM Jennison Health Sciences Fund | 183,037 | 1.27% | $21.68M | 1.56% | May 29, 2026 |
| T. Rowe Price New Horizons Fund, Inc. | 164,144 | 1.14% | $25.08M | 0.17% | Jun 30, 2026 |
| Federated Hermes Kaufmann Small Cap Fund | 150,500 | 1.04% | $20.93M | 0.73% | Jul 31, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 144,220 | 1.00% | $22.04M | 0.18% | Jun 30, 2026 |
| Fidelity Small Cap Growth Fund | 143,740 | 1.00% | $19.99M | 0.23% | Jul 31, 2026 |
| Fidelity Small Cap Index Fund | 120,068 | 0.83% | $16.69M | 0.05% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 113,586 | 0.79% | $17.36M | 0.02% | Jun 30, 2026 |
| AB Small Cap Growth Portfolio | 109,498 | 0.76% | $16.73M | 0.53% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Wes Kaupinen | President and CEO, Director, 10% owner | 1,607,228 | 11.15% | Feb 9, 2026 |
| Jeffrey S. Martini | Chief Scientific Officer | 0 | – | Nov 12, 2026 |
| Kathleen Goin | Chief Operating Officer | 0 | – | Oct 23, 2026 |
| Matthew E. Korenberg | CFO, Treasurer | 1,000 | 0.01% | Jun 16, 2026 |
| Ashley Hartmann Kline | Chief Commercial Officer | – | – | Feb 9, 2026 |
| Palvella Therapeutics, Inc. | CFO and Treasurer | – | – | Feb 7, 2025 |
| George M. Jenkins | Director | 146,132 | 1.01% | Oct 14, 2026 |
| Christopher P. Kiritsy | Director | 250 | 0.00% | Sep 4, 2026 |
| Matthew Pauls | Director | – | – | Jul 1, 2026 |
| John Doux | Director | – | – | Jun 12, 2026 |
| Tadd S. Wessel | Director | – | – | Jun 12, 2026 |
| Elaine J. Heron | Director | 53,691 | 0.37% | Jun 12, 2026 |
| Todd C. Davis | Director | 112,547 | 0.78% | Jun 12, 2026 |
| James A. Geraghty | Director | 0 | – | Dec 12, 2024 |
| Value Fund L. P. Biotechnology | – | 772,324 | 5.36% | Dec 17, 2024 |
| Ii Gp Llc Bvf | – | – | – | Dec 17, 2024 |
| Partners L. P/Il Bvf | – | – | – | Dec 17, 2024 |
| Mark N. Lampert | – | 425,346 | 2.95% | Dec 17, 2024 |
| Value Trading Fund OS LP Biotechnology | – | – | – | Dec 17, 2024 |
| Partners OS Ltd. BVF | – | 2,233,074 | 15.50% | Dec 17, 2024 |
| Value Fund Ii Lp Biotechnology | – | – | – | Dec 17, 2024 |
| I. Gp Llc Bvf | – | 282,223 | 1.96% | Dec 17, 2024 |
| Inc/Il Bvf | – | 2,408,207 | 16.71% | Dec 17, 2024 |
| Gp Holdings Llc Bvf | – | 8,581,171 | 59.56% | Dec 17, 2024 |
| Investments LP Dellora | – | 141,079 | 0.98% | Dec 16, 2024 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Jeffrey S. Martini Chief Scientific Officer | Nov 11, 2026 | Sale(10b5-1 plan) | −200 | $169.78 | $33.96K | 0 |
| Jeffrey S. Martini Chief Scientific Officer | Nov 11, 2026 | Sale(10b5-1 plan) | −600 | $168.73 | $101.24K | 200 |
| Jeffrey S. Martini Chief Scientific Officer | Nov 11, 2026 | Sale(10b5-1 plan) | −1,200 | $167.75 | $201.30K | 800 |
| Jeffrey S. Martini Chief Scientific Officer | Nov 11, 2026 | Sale(10b5-1 plan) | −1,133 | $166.76 | $188.94K | 2,000 |
| Jeffrey S. Martini Chief Scientific Officer | Nov 11, 2026 | Sale(10b5-1 plan) | −1,467 | $165.78 | $243.20K | 3,133 |
| Jeffrey S. Martini Chief Scientific Officer | Nov 11, 2026 | Sale(10b5-1 plan) | −1,650 | $164.14 | $270.83K | 4,600 |
| Jeffrey S. Martini Chief Scientific Officer | Nov 11, 2026 | Option exercise | +6,250 | $9.79 | $61.19K | 6,250 |
| Jeffrey S. Martini Chief Scientific Officer | Nov 10, 2026 | Sale(10b5-1 plan) | −800 | $172.12 | $137.70K | 0 |
| Jeffrey S. Martini Chief Scientific Officer | Nov 10, 2026 | Sale(10b5-1 plan) | −550 | $169.03 | $92.96K | 800 |
| Jeffrey S. Martini Chief Scientific Officer | Nov 10, 2026 | Sale(10b5-1 plan) | −200 | $167.81 | $33.56K | 1,350 |
| Jeffrey S. Martini Chief Scientific Officer | Nov 10, 2026 | Sale(10b5-1 plan) | −1,500 | $166.91 | $250.37K | 1,550 |
| Jeffrey S. Martini Chief Scientific Officer | Nov 10, 2026 | Sale(10b5-1 plan) | −1,651 | $165.85 | $273.81K | 3,050 |
| Jeffrey S. Martini Chief Scientific Officer | Nov 10, 2026 | Sale(10b5-1 plan) | −1,449 | $164.85 | $238.87K | 4,701 |
| Jeffrey S. Martini Chief Scientific Officer | Nov 10, 2026 | Sale(10b5-1 plan) | −100 | $163.34 | $16.33K | 6,150 |
| Jeffrey S. Martini Chief Scientific Officer | Nov 10, 2026 | Option exercise | +1,984 | $9.79 | $19.42K | 6,250 |
| Jeffrey S. Martini Chief Scientific Officer | Nov 10, 2026 | Option exercise | +4,266 | $7.53 | $32.12K | 4,266 |
| Kathleen Goin Chief Operating Officer | Oct 21, 2026 | Sale(10b5-1 plan) | −607 | $126.19 | $76.60K | 0 |
| Kathleen Goin Chief Operating Officer | Oct 21, 2026 | Sale(10b5-1 plan) | −1,663 | $125.16 | $208.15K | 607 |
| Kathleen Goin Chief Operating Officer | Oct 21, 2026 | Sale(10b5-1 plan) | −2,043 | $123.62 | $252.56K | 2,270 |
| Kathleen Goin Chief Operating Officer | Oct 21, 2026 | Option exercise | +2,148 | $9.08 | $19.50K | 4,313 |
| Kathleen Goin Chief Operating Officer | Oct 21, 2026 | Option exercise | +2,165 | $7.14 | $15.46K | 2,165 |
| George M. Jenkins Director | Oct 14, 2026 | Sale(10b5-1 plan) | −505 | $126.55 | $63.91K | 132,616 |
| George M. Jenkins Director | Oct 14, 2026 | Sale(10b5-1 plan) | −597 | $125.33 | $74.82K | 133,121 |
| George M. Jenkins Director | Oct 14, 2026 | Sale(10b5-1 plan) | −920 | $124.37 | $114.42K | 133,718 |
| George M. Jenkins Director | Oct 14, 2026 | Sale(10b5-1 plan) | −2,604 | $123.29 | $321.05K | 134,638 |
| George M. Jenkins Director | Oct 14, 2026 | Sale(10b5-1 plan) | −2,072 | $122.62 | $254.06K | 137,242 |
| George M. Jenkins Director | Oct 14, 2026 | Sale(10b5-1 plan) | −476 | $121.14 | $57.66K | 139,314 |
| George M. Jenkins Director | Oct 13, 2026 | Sale(10b5-1 plan) | −922 | $133.72 | $123.29K | 139,790 |
| George M. Jenkins Director | Oct 13, 2026 | Sale(10b5-1 plan) | −579 | $132.40 | $76.66K | 140,712 |
| George M. Jenkins Director | Oct 13, 2026 | Sale(10b5-1 plan) | −1,035 | $131.49 | $136.09K | 141,291 |
| George M. Jenkins Director | Oct 13, 2026 | Sale(10b5-1 plan) | −990 | $130.48 | $129.18K | 142,326 |
| George M. Jenkins Director | Oct 13, 2026 | Sale(10b5-1 plan) | −1,644 | $129.23 | $212.45K | 143,316 |
| George M. Jenkins Director | Oct 13, 2026 | Sale(10b5-1 plan) | −2,004 | $128.52 | $257.56K | 144,960 |
| George M. Jenkins Director | Oct 12, 2026 | Sale(10b5-1 plan) | −817 | $136.44 | $111.48K | 146,964 |
| George M. Jenkins Director | Oct 12, 2026 | Sale(10b5-1 plan) | −1,447 | $135.50 | $196.06K | 147,781 |
| George M. Jenkins Director | Oct 12, 2026 | Sale(10b5-1 plan) | −3,335 | $134.21 | $447.59K | 149,228 |
| George M. Jenkins Director | Oct 12, 2026 | Sale(10b5-1 plan) | −2,458 | $133.25 | $327.52K | 152,563 |
| George M. Jenkins Director | Oct 12, 2026 | Sale(10b5-1 plan) | −5,095 | $132.62 | $675.68K | 155,021 |
| Kathleen Goin Chief Operating Officer | Sep 16, 2026 | Option exercise | +2,148 | $9.08 | $19.50K | 4,302 |
| Kathleen Goin Chief Operating Officer | Sep 16, 2026 | Option exercise | +2,154 | $7.14 | $15.38K | 2,154 |
| Kathleen Goin Chief Operating Officer | Sep 16, 2026 | Sale(10b5-1 plan) | −1,659 | $151.16 | $250.77K | 2,643 |
| Kathleen Goin Chief Operating Officer | Sep 16, 2026 | Sale(10b5-1 plan) | −989 | $152.36 | $150.68K | 1,654 |
| Kathleen Goin Chief Operating Officer | Sep 16, 2026 | Sale(10b5-1 plan) | −1,654 | $153.24 | $253.46K | 0 |
| George M. Jenkins Director | Sep 15, 2026 | Sale(10b5-1 plan) | −263 | $150.40 | $39.56K | 160,676 |
| George M. Jenkins Director | Sep 15, 2026 | Sale(10b5-1 plan) | −954 | $149.38 | $142.51K | 160,939 |
| George M. Jenkins Director | Sep 15, 2026 | Sale(10b5-1 plan) | −560 | $151.33 | $84.74K | 160,116 |
| George M. Jenkins Director | Sep 14, 2026 | Sale(10b5-1 plan) | −1,560 | $153.10 | $238.84K | 161,893 |
| George M. Jenkins Director | Sep 14, 2026 | Sale(10b5-1 plan) | −6,160 | $152.12 | $937.06K | 163,453 |
| George M. Jenkins Director | Sep 14, 2026 | Sale(10b5-1 plan) | −5,632 | $151.46 | $853.02K | 169,613 |
| George M. Jenkins Director | Sep 11, 2026 | Sale(10b5-1 plan) | −6,520 | $150.62 | $982.04K | 181,096 |
| George M. Jenkins Director | Sep 11, 2026 | Sale(10b5-1 plan) | −4,577 | $151.72 | $694.42K | 176,519 |
| George M. Jenkins Director | Sep 11, 2026 | Sale(10b5-1 plan) | −1,274 | $153.06 | $195.00K | 175,245 |
| Christopher P. Kiritsy Director | Sep 2, 2026 | Sale | −313 | $157.00 | $49.14K | 250 |
| Christopher P. Kiritsy Director | Sep 2, 2026 | Option exercise | +313 | $127.20 | $39.81K | 563 |
| Kathleen Goin Chief Operating Officer | Aug 19, 2026 | Sale(10b5-1 plan) | −302 | $156.77 | $47.34K | 0 |
| Kathleen Goin Chief Operating Officer | Aug 19, 2026 | Option exercise | +2,154 | $7.14 | $15.38K | 2,154 |
| Kathleen Goin Chief Operating Officer | Aug 19, 2026 | Option exercise | +2,148 | $9.08 | $19.50K | 4,302 |
| Kathleen Goin Chief Operating Officer | Aug 19, 2026 | Sale(10b5-1 plan) | −1,500 | $151.39 | $227.08K | 2,802 |
| Kathleen Goin Chief Operating Officer | Aug 19, 2026 | Sale(10b5-1 plan) | −1,998 | $151.80 | $303.30K | 804 |
| Kathleen Goin Chief Operating Officer | Aug 19, 2026 | Sale(10b5-1 plan) | −400 | $153.00 | $61.20K | 404 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Palvella Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 5,700 shares on Sep 18, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Jeffrey S. Martini Officer | Nov 10, 2026 | 50,000 | $8.70M | Nov 10, 2026 | Exercise of Stock Options |
| Kathleen Goin Officer | Oct 21, 2026 | 4,313 | $534.47K | Oct 21, 2026 | Stock Option Exercise |
| George M. Jenkins Director | Oct 13, 2026 | 27,500 | $3.70M | Oct 13, 2026 | Private Investment |
| Kathleen Goin Officer | Sep 16, 2026 | 4,302 | $650.55K | Sep 16, 2026 | Stock Option Exercise |
| George M. Jenkins Director | Sep 11, 2026 | 27,500 | $4.14M | Sep 11, 2026 | Private Investment |
| Christopher P. Kiritsy Director | Sep 2, 2026 | 375 | $58.88K | Sep 2, 2026 | Stock Option Exercise |
| Kathleen Goin Officer | Aug 19, 2026 | 4,302 | $647.11K | Aug 19, 2026 | Stock Option Exercise |
| Kathleen Goin Officer | Jul 15, 2026 | 4,302 | $643.92K | Jul 15, 2026 | Stock Option Exercise |
| Kathleen Goin Officer | Jun 17, 2026 | 4,302 | $476.37K | Jun 17, 2026 | Stock Option Exercise |
| Kathleen Goin Officer | May 20, 2026 | 4,302 | $475.63K | May 20, 2026 | Stock Option Exercise |
| Kathleen Goin Officer | Apr 15, 2026 | 4,302 | $557.24K | Apr 15, 2026 | Stock Option Exercise |
| Kathleen Goin Officer | Mar 18, 2026 | 4,302 | $519.68K | Mar 18, 2026 | Stock Option |
| Kathleen Goin Officer | Feb 19, 2026 | 4,302 | $344.55K | Feb 18, 2026 | Stock Option Exercise |
| Kathleen Goin Officer | Feb 18, 2026 | 4,301 | $344.47K | Feb 18, 2026 | Option Exercise |
| Kathleen Goin Officer | Jan 21, 2026 | 4,302 | $421.64K | Jan 21, 2026 | Stock Option Exercise |
See a number that looks wrong?